FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
esmo - Evidence for efficacy is based on the findings from the ROSELLA study
AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.
Related Stories
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 21 days
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 5 wks
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 1 month
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 14 days
Datroway secures regulatory approvals in breast cancer across US and EU / 7 wks
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supply Chain, Infant Health, Diagnostics, Genetics and look for the RSS link.
StackHealth Time Machine